Hochman David P's Form 4/A amendment
AmendedOrchestra BioMed Holdings, Inc. (OBIO) · filed May 21, 2024
- Accession no.
- 0001104659-24-064004
- Filed
- May 21, 2024
- Trade date
- May 16-17, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 20, 2024
This filing lists 2 non-derivative transactions. Open-market purchases total $24.9K. It was filed 5 days after the trade.
This amendment replaces 0001104659-24-063414 (filed May 20, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hochman David PCIK 0001292834 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 20, 2024, the Reporting Person filed a Form 4 which inadvertently misstated the transaction codes in Column 3 of Table I. This amendment is filed solely to correct the transaction codes in Column 3 of Table I to "P". The remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.74 to $4.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Executive Officer and Chairperson